Building an External Control Arm for Development of a New Molecular Entity: An Application in a Recurrent Glioblastoma Trial for MDNA55
Author:
Publisher
Springer Science and Business Media LLC
Subject
Biochemistry, Genetics and Molecular Biology (miscellaneous),Statistics and Probability
Link
https://link.springer.com/content/pdf/10.1007/s12561-022-09337-7.pdf
Reference21 articles.
1. Nabors LB et al (2020) Central nervous system cancers, Version 3.2020 NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 18(11):1537–1570
2. Arrillaga-Romany I, Sahebjam S, Picconi D, et al (2019) ACTR-61. A Randomized Phase 2 Trial of Cendiranib in Combination with Olaparib versus Bevacizumab in Patients with Recurrent Glioblastoma, Neuro-Oncology, vi27
3. Cloughesy TF, Petrecca K, Walbert T et al (2020) Effect of vocimagene amiretrorepvec in combination with flucytosine vs standard of care on survival following tumor resection in patients with recurrent high-grade glioma: a randomized clinical trial. JAMA Oncol 6(12):1939–1946
4. Reardon DA, Brandes AA, Omuro A et al (2020) Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 Phase 3 randomized clinical trial. JAMA Oncol 6(7):1003–1010
5. Rosenbaum PR, Rubin DB (1983) The central role of the propensity score in observational studies for causal effects. Biometrika 70:41–55
Cited by 7 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Augmenting external control arms using Bayesian borrowing: a case study in first-line non-small cell lung cancer;Journal of Comparative Effectiveness Research;2024-05
2. The Next Horizon of Drug Development: External Control Arms and Innovative Tools to Enrich Clinical Trial Data;Therapeutic Innovation & Regulatory Science;2024-03-25
3. Current drug development and trial designs in neuro-oncology: report from the first American Society of Clinical Oncology and Society for Neuro-Oncology Clinical Trials Conference;The Lancet Oncology;2023-04
4. Development of an External Control Arm Using Electronic Health Record‐Based Real‐World Data to Evaluate the Efficacy of COVID‐19 Treatment;Clinical Pharmacology & Therapeutics;2023-03-20
5. Phase II trials in the era of glioblastoma immunotherapy: New mechanisms of action, familiar challenges in trial design and tumor response assessment;Neuro-Oncology;2023-02-15
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3